NDATOPICALLOTION
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
SKLICE (ivermectin) by R-Pharm US is 12. First approved in 2012.
Drug data last refreshed 5h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SKLICE (ivermectin 1% cream) is a topical antiparasitic agent approved for treating rosacea lesions, though its exact mechanism of action remains unknown. It is absorbed systemically with a half-life of 6.5 days and does not accumulate over extended treatment periods. The drug represents an off-label repurposing of ivermectin, traditionally used for parasitic infections, into dermatology.
Peak
Peak lifecycle status indicates established market presence with mature commercial infrastructure, though limited publicly available spending data suggests modest revenue relative to blockbuster dermatology brands.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At therapeutic doses, ivermectin cream is not expected to prolong QTc interval. 12.3 Pharmacokinetics Absorption The absorption of ivermectin…
Pharmacologic Class:
Antiparasitic
Indications
Worked on SKLICE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.